Cullen R T, McCrae W M, Govan J, Raeburn J A, Ingram T M
J Antimicrob Chemother. 1983 Jul;12 Suppl A:369-75. doi: 10.1093/jac/12.suppl_a.369.
We have investigated the use of the new cephalosporin ceftazidime for the treatment of pseudomonas infection in cystic fibrosis, using 100 to 240 mg/kg intravenously daily. The clinical and microbiological results of 18 courses of therapy, lasting from 1 to 4 weeks have been satisfactory, particularly since the patients had previously proved refractory to treatment with most other appropriate antibiotics. However, in common with other anti-pseudomonal antibiotics, a first course of ceftazidime proved the most successful, subsequent courses being less effective. Three patients died because of chronic respiratory infection. In cystic fibrosis pseudomonal infections rapidly relapse after therapy and therefore we have been examining the interactions of antibiotics with relevant host defence mechanisms. In one patient who received a 4 g infusion of ceftazidime there was enhancement of neutrophil phagocytosis-triggered chemiluminescence. We conclude that, used in high doses, ceftazidime is a useful addition to the available antibiotics for therapy of pseudomonas infection in cystic fibrosis.
我们研究了新型头孢菌素头孢他啶用于治疗囊性纤维化患者假单胞菌感染的情况，静脉注射剂量为每日100至240毫克/千克。18个疗程的治疗，持续1至4周，临床和微生物学结果均令人满意，特别是因为这些患者先前已证明对大多数其他合适的抗生素治疗无效。然而，与其他抗假单胞菌抗生素一样，头孢他啶的首个疗程最为成功，后续疗程效果较差。3名患者因慢性呼吸道感染死亡。在囊性纤维化中，假单胞菌感染在治疗后迅速复发，因此我们一直在研究抗生素与相关宿主防御机制的相互作用。在一名接受4克头孢他啶静脉输注的患者中，中性粒细胞吞噬引发的化学发光增强。我们得出结论，高剂量使用时，头孢他啶是治疗囊性纤维化假单胞菌感染的现有抗生素中的一种有用补充。
